[go: up one dir, main page]

CL2017000804A1 - Derivados espirodiamina como inhibidores de la aldosterona sintasa - Google Patents

Derivados espirodiamina como inhibidores de la aldosterona sintasa

Info

Publication number
CL2017000804A1
CL2017000804A1 CL2017000804A CL2017000804A CL2017000804A1 CL 2017000804 A1 CL2017000804 A1 CL 2017000804A1 CL 2017000804 A CL2017000804 A CL 2017000804A CL 2017000804 A CL2017000804 A CL 2017000804A CL 2017000804 A1 CL2017000804 A1 CL 2017000804A1
Authority
CL
Chile
Prior art keywords
spirodiamine
derivatives
synthase inhibitors
aldosterone synthase
compounds
Prior art date
Application number
CL2017000804A
Other languages
English (en)
Inventor
Johannes Aebi
Kurt E Amrein
Junli Chen
Benoit Hornsperger
Bernd Kuhn
Yongfu Liu
Dongbo Li
Hans Peter Maerki
Rainer E Martin
Alexander Mayweg
Xuefei Tan
Jun Wu
Jianhua Yu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54256743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000804(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017000804A1 publication Critical patent/CL2017000804A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>LA INVENCIÓN PROPORCIONA NUEVOS COMPUESTOS QUE PRESENTAN LA FORMULA GENERAL (I), EN LA QUE R1, R2, R3, R4 R5, R6, R7, R8, R9, R10 R11,R12,R13,R14,R15, A1, A2,M, N Y P SON TAL COMO SE INDICA EN LA PRESENTE MEMORIA, COMPOSICIONES QUE INCLUYEN LOS COMPUESTOS Y MÉTODOS DE UTILIZACIÓN DE LOS COMPUESTOS.</p>
CL2017000804A 2014-10-08 2017-04-03 Derivados espirodiamina como inhibidores de la aldosterona sintasa CL2017000804A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014088133 2014-10-08

Publications (1)

Publication Number Publication Date
CL2017000804A1 true CL2017000804A1 (es) 2017-12-15

Family

ID=54256743

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000804A CL2017000804A1 (es) 2014-10-08 2017-04-03 Derivados espirodiamina como inhibidores de la aldosterona sintasa

Country Status (21)

Country Link
US (1) US10035804B2 (es)
EP (1) EP3204383B1 (es)
JP (1) JP6613306B2 (es)
KR (1) KR102550852B1 (es)
CN (1) CN106852142B (es)
AU (1) AU2015330141B2 (es)
BR (1) BR112017006829B1 (es)
CA (1) CA2962122A1 (es)
CL (1) CL2017000804A1 (es)
CO (1) CO2017003132A2 (es)
CR (1) CR20170118A (es)
EA (1) EA035185B1 (es)
ES (1) ES2850198T3 (es)
IL (1) IL251106B (es)
MX (1) MX381729B (es)
PE (1) PE20171057A1 (es)
PH (1) PH12017500658A1 (es)
SG (1) SG11201702335VA (es)
UA (1) UA122061C2 (es)
WO (1) WO2016055394A1 (es)
ZA (1) ZA201701846B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
SMT201900620T1 (it) 2014-02-13 2020-01-14 Incyte Corp Ciclopropilammine come inibitori di lsd1
WO2015123465A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
PH12018500317B1 (en) 2015-08-12 2023-01-11 Incyte Holdings Corp Salts of an lsd1 inhibitor
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3600290B1 (en) * 2017-03-21 2025-06-04 Temple University - Of The Commonwealth System of Higher Education Novel modulators of the sigma-2 receptor and their method of use
US20200115353A1 (en) 2017-04-06 2020-04-16 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
JP2021532157A (ja) * 2018-08-01 2021-11-25 アラクセス ファーマ エルエルシー がんを処置するための複素環式スピロ化合物およびその使用方法
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664213B2 (en) * 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
US9073881B2 (en) * 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
CN103958478B (zh) * 2011-11-30 2017-08-01 霍夫曼-拉罗奇有限公司 双环二氢异喹啉‑1‑酮衍生物
EA035454B1 (ru) * 2011-11-30 2020-06-18 Ф.Хоффманн-Ля Рош Аг Бициклические производные дигидроизохинолин-1-она
ES2804271T3 (es) * 2013-05-27 2021-02-05 Hoffmann La Roche Nuevos compuestos de 3,4-dihidro-2H-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
ES2763424T3 (es) * 2013-05-27 2020-05-28 Hoffmann La Roche Nuevos compuestos de 3,4-dihidro-2H-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
CA2903180C (en) * 2013-05-27 2022-03-15 F. Hoffmann-La Roche Ag 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds

Also Published As

Publication number Publication date
KR20170057307A (ko) 2017-05-24
IL251106A0 (en) 2017-04-30
WO2016055394A1 (en) 2016-04-14
KR102550852B1 (ko) 2023-07-05
EP3204383A1 (en) 2017-08-16
CR20170118A (es) 2017-07-10
AU2015330141B2 (en) 2019-12-05
PE20171057A1 (es) 2017-07-21
IL251106B (en) 2020-04-30
SG11201702335VA (en) 2017-04-27
US10035804B2 (en) 2018-07-31
UA122061C2 (uk) 2020-09-10
CN106852142B (zh) 2020-08-21
BR112017006829A2 (pt) 2017-12-12
CO2017003132A2 (es) 2017-07-11
JP6613306B2 (ja) 2019-11-27
ZA201701846B (en) 2018-05-30
EA201790765A1 (ru) 2017-08-31
MX2017004541A (es) 2017-06-27
JP2017534606A (ja) 2017-11-24
AU2015330141A1 (en) 2017-03-30
MX381729B (es) 2025-03-13
CN106852142A (zh) 2017-06-13
PH12017500658B1 (en) 2017-10-02
EA035185B1 (ru) 2020-05-12
ES2850198T3 (es) 2021-08-26
PH12017500658A1 (en) 2017-10-02
US20170204107A1 (en) 2017-07-20
NZ729966A (en) 2024-02-23
CA2962122A1 (en) 2016-04-14
EP3204383B1 (en) 2020-11-18
BR112017006829B1 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
CL2017000804A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
CL2017002908A1 (es) Amidas heterocíclicas como inhibidores de quinasa.
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
CL2017002452A1 (es) Nuevos compuestos bicíclicos
UA115972C2 (uk) Біциклічні похідні дигідрохінолін-2-ону
CL2019002609A1 (es) Compuestos heterocíclicos útiles como inhibidores dobles atx/ca.
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
CR20150420A (es) Amidas heterocíclicas como inhibidores de cinasas
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
NI201500119A (es) Compuestos de heteroarilo y sus usos
MX2016010675A (es) Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
MX374558B (es) Compuestos de heteroarilo y sus usos.
MX380146B (es) Inhibidores mk2 y usos de los mismos.
CR20140135A (es) Nuevos derivados de aril-quinolina
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CU20160010A7 (es) NUEVOS COMPUESTOS ISOINDOLlNA O ISOQUINOLlNA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS Bcl-2 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
ECSP15050110A (es) Derivados de triazina
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
MX2015011005A (es) Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.